LENZ Therapeutics

LENZ Therapeutics - a high risk high reward small cap biotech stock

MotherHorseEyes

Invested

Community Contributor

Published

17 Sep 25

MotherHorseEyes's Fair Value

US$200.00

79.4% undervalued

17 Sep

US$41.29

95.7%

3.5%

95.7%

3.5%

You can edit this narrative until Sep 18 10:47 AM. Then, changes will post as Updates.

Author's Valuation

US$200.0

79.4% undervalued

MotherHorseEyes's Fair Value

Narrative

Updates0

MotherHorseEyes'sFair Value

US$200

79.4% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

55.99%

Pharma revenue growth rate

0.60%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$379.72m

Earnings '30

25.02x

PE Ratio '30

US$9.50b

Market Cap '30

US$9.50b

Market Cap '30

34.23m

No. shares '30

US$277.58

Share Price '30

US$277.58 Share Price '30

Discounted to 2025 @ 6.78% p.a.

US$200.00

Fair Value '25